ICLR vs MEDP vs EVO Stock Comparison

Icon, Medpace Holdings and Evotec SE Prices as of Nov 13, 2026 Peers: Industry group
ICLR Icon Plc
$194.65 +15.2% 1M +19.1% 1Y
Market cap
$14.98B
P/E
33.4x
Revenue (TTM)
$8.23B
Div. yield
–
Contract Research Healthcare
4 wins
MEDP Medpace Holdings, Inc.
$653.94 +6.1% 1M +10.6% 1Y
Market cap
$18.22B
P/E
35.2x
Revenue (TTM)
$2.84B
Div. yield
–
Contract Research Healthcare
5 wins
EVO Evotec SE
$1.58 +11.3% 1M -50.2% 1Y
Market cap
$561.15M
P/E
–
Revenue (TTM)
—
Div. yield
–
Contract Research Healthcare

Head to Head

9 decided of 12

Medpace Holdings leads on 5 of the 12 questions below (Medpace Holdings 5, Icon 4). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionICLRMEDPEVOLeader
Larger companyMarket capitalisation $14.98B $18.22B $561.15M MEDP
Cheaper on earningsLower P/E, profitable companies only 33.4x 35.2x — ICLR
Cheaper on forward earningsLower price / next fiscal year consensus EPS 19.0x 36.7x — ICLR
Faster revenue growthRevenue growth, trailing twelve months +1.8% +20.4% — MEDP
More profitableNet margin, trailing twelve months 5.4% 18.2% — MEDP
Better return on capitalReturn on invested capital 4.7% — — –
Less leveragedLower net debt / EBITDA 2.3x — — –
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +19.1% +10.6% -50.2% ICLR
Better 5-year returnAnnualised price return, 5 years -7.4%/yr +24.2%/yr -41.8%/yr MEDP
Less volatileAnnualised volatility, 1 year 74.9% 46.0% 56.8% MEDP
Higher overall scoreMean of the five percentile scores vs peers 78/100 67/100 — ICLR

Percentile Scorecard

ICLRMEDPEVO

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisICLRMEDPEVO
Valuation 100 #1 of 11 60 #5 of 11 –
Growth 50 #6 of 11 100 #1 of 11 –
Profitability 80 #3 of 11 100 #1 of 11 –
Financial Health 75 #4 of 13 33 #9 of 13 83 #3 of 13
Shareholder Returns 86 #2 of 8 43 #5 of 8 –
Overall 78 67 –
  • ICLR ranked among 13 companies in Pharma Services
  • MEDP ranked among 13 companies in Pharma Services
  • EVO ranked among 13 companies in Pharma Services

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodICLRMEDPEVOSPY
1 month +15.2%+6.1%+11.3% -2.0%
3 months +19.3%+13.0%-19.4% -2.8%
6 months +67.3%+57.5%-41.5% +2.0%
Year to date +6.8%+16.4%-48.7% +10.6%
1 year +19.1%+10.6%-50.2% +12.2%
3 years -27.1%+131.8%-84.3% +68.1%
3 years, per year -10.0%+32.4%-46.1% +18.9%
5 years -31.8%+194.7%-93.3% +61.4%
5 years, per year -7.4%+24.2%-41.8% +10.1%
10 years +142.7%+1,803.8%— +248.5%
10 years, per year +9.3%+34.3%— +13.3%

Risk

MeasureICLRMEDPEVOSPY
Volatility, 1Y 74.9%46.0%56.8% 13.6%
Downside volatility, 1Y 87.1%54.0%61.3% 13.9%
Beta vs S&P 500, 1Y 1.290.721.14 1.00
Return / volatility, 1Y 0.250.23-0.88 0.90
Max drawdown, 5Y -76.9%-42.9%-94.6% -25.4%
From 52-week high -9.7%-5.6%-59.2% -3.2%
52-week high $215.48$692.68$3.87 $779.14
52-week low $80.08$393.42$1.35 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleICLRMEDPEVO
P/E now vs peer median 34.0xmedian 34.7x 35.3xmedian 34.7x —median 34.7x
P/S now vs peer median 1.8xmedian 2.5x 6.4xmedian 2.5x —median 2.5x
EV/EBITDA now vs peer median 16.0xmedian 29.1x 27.7xmedian 29.1x —median 29.1x
P/FCF now vs peer median 17.4xmedian 21.0x 27.4xmedian 21.0x —median 21.0x
P/B now vs peer median 1.6xmedian 1.6x 31.3xmedian 1.6x 0.8xmedian 1.6x
PEG now vs peer median -11.35median 1.98 1.24median 1.98 —median 1.98

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsICLRMEDPEVO
Revenue $8.23B $2.84B –
Gross profit $1.93B $827.16M –
Operating income $718.25M $607.14M –
Net income $448.66M $517.83M –
Free cash flow $857.06M $667.63M –
EPS (diluted) $5.68 $18.25 –
Cash & equivalents $808.98M $705.32M $339.10M
Total debt $3.38B – $546.42M
Shares (diluted) 78.97M 28.37M –
Enterprise value $11.75B $15.86B -$1.20B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricICLRMEDPEVO
P/E 34.0x 35.3x –
P/FCF 17.4x 27.4x –
P/Operating cash flow 14.5x 25.3x –
P/S 1.8x 6.4x –
P/B 1.6x 31.3x 0.8x
P/Tangible book 2.5x 33.1x 0.8x
EV/EBITDA 16.0x 27.7x –
EV/EBIT 24.3x 29.0x –
EV/Revenue 2.1x 6.2x –
EV/FCF 20.4x 26.3x –
EV/Operating cash flow 17.0x 24.3x –
PEG (3Y EPS CAGR) -11.35 1.24 –

Growth

14 metrics
MetricICLRMEDPEVO
Revenue growth (1Y) 1.8% 20.4% –
Revenue CAGR (3Y) 0.9% 16.8% –
Gross profit growth (1Y) -13.4% 12.8% –
Gross profit CAGR (3Y) -6.5% 18.0% –
Operating income growth (1Y) 53.9% 19.7% –
Operating income CAGR (3Y) -7.0% 23.0% –
Net income growth (1Y) 55.9% 19.6% –
Net income CAGR (3Y) -4.4% 23.8% –
EPS growth (1Y) 30.1% 21.5% –
EPS CAGR (3Y) -3.0% 28.5% –
Operating cash flow growth (1Y) -9.9% 1.7% –
Operating cash flow CAGR (3Y) 15.8% 20.5% –
Free cash flow growth (1Y) -11.1% -1.4% –
Free cash flow CAGR (3Y) 18.4% 20.9% –

Profitability

14 metrics
MetricICLRMEDPEVO
Gross margin 23.4% 29.1% –
EBITDA margin 13.3% 22.4% –
Operating margin 8.7% 21.4% –
Pretax margin 6.3% 22.1% –
Net margin 5.4% 18.2% –
FCF margin 10.4% 23.5% –
Operating cash flow margin 12.5% 25.5% –
Return on equity 7.6% 101.7% –
Return on assets 4.3% 23.8% –
Return on invested capital 4.7% – –
Return on capital employed 5.3% 88.8% –
Asset turnover 0.5x 1.3x –
Cash conversion (OCF / net income) 2.3x 1.4x –
Stock comp / revenue 1.1% 0.8% –

Financial Health

11 metrics
MetricICLRMEDPEVO
Debt / assets 20.8% – 32.0%
Debt / equity 0.4x – 0.8x
Net debt / EBITDA 2.3x – –
Debt / FCF 3.9x – –
Liabilities / assets 43.8% 74.6% 57.4%
Equity / assets 56.2% 25.4% 42.6%
Interest coverage 3.4x – –
Current ratio 1.3x 0.8x 2.3x
Quick ratio 0.9x 0.8x 1.6x
Cash ratio 0.3x 0.5x 1.1x
Altman Z-score 2.15 8.13 –

Shareholder Returns

7 metrics
MetricICLRMEDPEVO
Dividend yield – – –
Net buyback yield 2.6% 1.3% –
Shareholder yield 2.6% 1.3% 0.0%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusICLRMEDPEVO
Forward P/E 19.0xFY2026 36.7xFY2026 –
EPS, next fiscal year $10.26FY2026 $17.80FY2026 $-0.75FY2026
EPS growth, next FY -18.1%FY2026 +16.5%FY2026 –
EPS growth, the year after +20.1% +6.2% –
Revenue, next fiscal year $8.54BFY2026 $2.94BFY2026 $694.45MFY2026
Revenue growth, next FY +3.5%FY2026 +16.4%FY2026 -24.7%FY2026
Revenue growth, the year after -2.2% +6.0% +13.4%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersICLRMEDPEVO
Held by institutions 100.0% 87.8% 0.9%
Institutions holding 424 695 35
Change in shares held, QoQ +5.5% +3.2% -60.2%
Institutions buying 233 279 18
Institutions selling 139 304 7
Buyers to sellers 1.68 0.92 2.57

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

ICLRMEDPEVO
ICLR 1.00 0.38 0.22
MEDP 0.38 1.00 0.21
EVO 0.22 0.21 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, ICLR, MEDP and EVO?

Medpace Holdings (MEDP) is the largest by market capitalisation: Icon (ICLR) $14.98B, Medpace Holdings (MEDP) $18.22B, Evotec SE (EVO) $561.15M.

Which stock is cheaper, ICLR, MEDP and EVO?

Icon (ICLR) trades on the lowest price-to-earnings ratio (Icon (ICLR) 33.4x, Medpace Holdings (MEDP) 35.2x). On next year's consensus earnings, Icon (ICLR) is cheapest (Icon (ICLR) 19.0x, Medpace Holdings (MEDP) 36.7x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Medpace Holdings (MEDP) grew revenue fastest over the trailing twelve months: Icon (ICLR) +1.8%, Medpace Holdings (MEDP) +20.4%.

Which company is more profitable?

Medpace Holdings (MEDP) has the highest net margin (Icon (ICLR) 5.4%, Medpace Holdings (MEDP) 18.2%).

Which stock has performed better?

Over the past year Icon (ICLR) returned the most: Icon (ICLR) +19.1%, Medpace Holdings (MEDP) +10.6%, Evotec SE (EVO) -50.2%. Over five years, Medpace Holdings (MEDP) compounded fastest (Icon (ICLR) -7.4%/yr, Medpace Holdings (MEDP) +24.2%/yr, Evotec SE (EVO) -41.8%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Medpace Holdings (MEDP) has been the steadiest (Icon (ICLR) 74.9%, Medpace Holdings (MEDP) 46.0%, Evotec SE (EVO) 56.8%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, ICLR, MEDP and EVO?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Medpace Holdings (MEDP) leads on 5. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.